
zzso human tumor necrosis factor zzso is a zzso zzso with zzso zzso A phase I trial of zzso was initiated using a five-day continuous intravenous zzso infusion repeated every 28 zzso zzso courses of therapy were administered to 19 zzso The starting dose was 5 X zzso zzso with zzso to zzso X zzso zzso X zzso zzso X zzso and zzso X zzso zzso zzso side effects, including fever, zzso zzso fatigue, zzso and zzso were mild and zzso At the maximum tolerated dose of zzso X zzso zzso zzso zzso toxicity was zzso by transient zzso and zzso zzso zzso levels were also seen at the higher dose zzso zzso analysis demonstrated that the five-day treatment with zzso was associated with decreases in zzso zzso as well as increases in zzso and zzso zzso zzso studies using an zzso zzso zzso zzso test indicated plasma zzso levels less than zzso zzso The recommended phase II dose of zzso administered as a five-day continuous infusion is zzso X zzso zzso 

